

A panel of MHC class I restricted viral peptides for use a
trial ELISPOT assays

Journal of Immunological Methods

260, 157-172

DOI: [10.1016/s0022-1759\(01\)00535-x](https://doi.org/10.1016/s0022-1759(01)00535-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cross-Clade T Lymphocyte-Mediated Immunity to HIV Type 1: Implications for Vaccine Design and Immunodetection Assays. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 1067-1079.	0.5	22
2	The ELISPOT Assay: An Easily Transferable Method for Measuring Cellular Responses and Identifying T Cell Epitopes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 903-10.	1.4	57
3	HIV vaccines: Biological and clinical considerations. <i>Current Infectious Disease Reports</i> , 2002, 4, 359-368.	1.3	2
4	Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. <i>Journal of Immunological Methods</i> , 2003, 283, 141-153.	0.6	200
5	Baculovirus virions displaying Plasmodium berghei circumsporozoite protein protect mice against malaria sporozoite infection. <i>Virology</i> , 2003, 316, 161-170.	1.1	57
6	CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. <i>Journal of Immunological Methods</i> , 2003, 278, 79-93.	0.6	169
7	Functional supertype of HLA-A2 in the presentation of Flu matrix p58-66 to induce CD8+ T-cell response in a Northern Chinese population. <i>Tissue Antigens</i> , 2003, 62, 285-295.	1.0	26
8	HIV vaccines 1983â€“2003. <i>Nature Medicine</i> , 2003, 9, 874-880.	15.2	240
9	The HIV-1 chimeric protein CR3 expressed by poxviral vectors induces a diverse CD8+ T cell response in mice and is antigenic for PBMCs from HIV+ patients. <i>Vaccine</i> , 2003, 22, 145-155.	1.7	2
10	Moving to Human Immunodeficiency Virus Type 1 Vaccine Efficacy Trials: Defining T Cell Responses As Potential Correlates of Immunity. <i>Journal of Infectious Diseases</i> , 2003, 187, 226-242.	1.9	118
11	Longitudinal Assessment of Changes in HIV-Specific Effector Activity in HIV-Infected Patients Starting Highly Active Antiretroviral Therapy in Primary Infection. <i>Journal of Immunology</i> , 2003, 171, 477-488.	0.4	45
12	Human Immunodeficiency Virus: Scientific Challenges Impeding Candidate Vaccines. <i>HIV Clinical Trials</i> , 2003, 4, 421-424.	2.0	3
14	Clearance of Hepatitis C Viremia Associated with Cellular Immunity in the Absence of Seroconversion in the Hepatitis C Incidence and Transmission in Prisons Study Cohort. <i>Journal of Infectious Diseases</i> , 2004, 189, 1846-1855.	1.9	147
15	Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. <i>International Immunology</i> , 2004, 17, 167-176.	1.8	26
16	Identification of a Naturally Processed Cytotoxic CD8 T-Cell Epitope of Coxsackievirus B4, Presented by HLA-A2.1 and Located in the PEVKEK Region of the P2C Nonstructural Protein. <i>Journal of Virology</i> , 2004, 78, 13399-13408.	1.5	31
17	Hierarchical Targeting of Subtype C Human Immunodeficiency Virus Type 1 Proteins by CD8 + T Cells: Correlation with Viral Load. <i>Journal of Virology</i> , 2004, 78, 3233-3243.	1.5	202
18	Correlation between Interferon- γ Secretion and Cytotoxicity, in Virus-Specific Memory T Cells. <i>Journal of Infectious Diseases</i> , 2004, 190, 1692-1696.	1.9	37
19	Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation. <i>Journal of Experimental Medicine</i> , 2004, 199, 1133-1142.	4.2	162

#	ARTICLE	IF	CITATIONS
20	Memory T-Cell-Mediated Immune Responses Specific to an Alternative Core Protein in Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2004, 78, 10460-10469.	1.5	70
21	DNA vaccines against human immunodeficiency virus type 1. <i>Immunological Reviews</i> , 2004, 199, 144-155.	2.8	39
22	Evaluation of Elispot assays: influence of method and operator on variability of results. <i>Journal of Immunological Methods</i> , 2004, 291, 175-183.	0.6	51
23	Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. <i>Journal of Translational Medicine</i> , 2004, 2, 31.	1.8	29
24	Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4+ T cells to HIV-infected persons. <i>Clinical Immunology</i> , 2004, 111, 262-274.	1.4	25
25	Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 259-268.	2.0	29
26	Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes. <i>Human Immunology</i> , 2004, 65, 1307-1318.	1.2	23
27	Tc1 effector diversity shows dissociated expression of granzyme B and interferon- γ in HIV infection. <i>Aids</i> , 2004, 18, 383-392.	1.0	29
28	Impact of intrapeptide epitope location on CD8 T cell recognition. <i>Aids</i> , 2004, 18, 871-876.	1.0	36
29	Ex Vivo Analysis of Human Antigen-Specific CD8+ T-Cell Responses: Quality Assessment of Fluorescent HLA-A2 Multimer and Interferon- γ ELISPOT Assays for Patient Immune Monitoring. <i>Journal of Immunotherapy</i> , 2004, 27, 298-308.	1.2	40
30	Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells. <i>Journal of Immunotherapy</i> , 2005, 28, 28-39.	1.2	20
31	Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. <i>Blood</i> , 2005, 106, 2903-2911.	0.6	430
32	Interferon- γ ELISPOT Assay for the Quantitative Measurement of Antigen-Specific Murine CD8+ T-Cells. , 2005, 302, 191-204.		10
33	Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2005, 36, 411-415.	1.3	30
34	Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. <i>Cellular Immunology</i> , 2005, 235, 29-38.	1.4	56
35	IL-2 absorption affects IFN- γ and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays. <i>Cellular Immunology</i> , 2005, 237, 28-36.	1.4	32
36	A vaccinia-based elispot assay for detection of CD8+ T cells from HIV-1 infected children. <i>Journal of Immunological Methods</i> , 2005, 298, 105-118.	0.6	9
37	Standardization of cytokine flow cytometry assays. <i>BMC Immunology</i> , 2005, 6, 13.	0.9	203

#	ARTICLE	IF	CITATIONS
38	CD8+ T?cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses. European Journal of Immunology, 2005, 35, 159-170.	1.6	41
39	Immune responses to Plasmodium vivax pre-erythrocytic stage antigens in naturally exposed Duffy-negative humans: a potential model for identification of liver-stage antigens. European Journal of Immunology, 2005, 35, 1859-1868.	1.6	25
40	Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology, 2005, 42, 104-112.	3.6	211
41	Recovery of CD8+ T-Cell Function During Systemic Chemotherapy in Advanced Ovarian Cancer. Cancer Research, 2005, 65, 7000-7006.	0.4	72
42	Cross-reactivity of Anti-HIV-1 T Cell Immune Responses among the Major HIV-1 Clades in HIV-1 Positive Individuals from 4 Continents. Journal of Infectious Diseases, 2005, 191, 1427-1434.	1.9	72
43	Use of Interferon- γ ELISPOT in Monitoring Immune Responses in Humans. , 2005, 302, 237-252.		5
44	Standardization and Validation Issues of the ELISPOT Assay. , 2005, 302, 051-086.		60
45	Results of an ELISPOT Proficiency Panel Conducted in 11 Laboratories Participating in International Human Immunodeficiency Virus Type 1 Vaccine Trials. AIDS Research and Human Retroviruses, 2005, 21, 68-81.	0.5	85
46	Single-Round HIV Type 1 Neutralization Measured by ELISPOT Technique in Primary Human Cells. AIDS Research and Human Retroviruses, 2005, 21, 784-790.	0.5	3
47	Depletion of Regulatory T Cells in HIV Infection Is Associated with Immune Activation. Journal of Immunology, 2005, 174, 4407-4414.	0.4	337
48	HIV-1-specific IFN- γ /IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7239-7244.	3.3	277
49	HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13980-13985.	3.3	141
50	Cellular immune selection with hepatitis C virus persistence in humans. Journal of Experimental Medicine, 2005, 201, 1741-1752.	4.2	278
51	Human Immunodeficiency Virus (HIV)-Specific Gamma Interferon Secretion Directed against All Expressed HIV Genes: Relationship to Rate of CD4 Decline. Journal of Virology, 2005, 79, 4908-4917.	1.5	32
52	Detection of human perforin by ELISpot and ELISA: Ex vivo identification of virus-specific cells. Journal of Immunological Methods, 2005, 302, 13-25.	0.6	54
53	Characterization of Host Immunity to cytomegalovirus pp150 (UL32). Human Immunology, 2005, 66, 116-126.	1.2	22
54	Dendritic Cells Expand Epstein Barr Virus Specific CD8+ T Cell Responses More Efficiently Than EBV Transformed B Cells. Human Immunology, 2005, 66, 938-949.	1.2	21
55	Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma. Vaccine, 2005, 23, 2399-2402.	1.7	3

#	ARTICLE	IF	CITATIONS
57	Characterization of the IFN-gamma T-cell responses to immediate early antigens in humans with genital herpes. <i>Virology Journal</i> , 2006, 3, 54.	1.4	15
58	Defective IL-2 Production by HIV-1-Specific CD4 and CD8 T Cells in an Adolescent/Young Adult Cohort. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 272-282.	0.5	15
59	Measurement of cytokine release at the single cell level using the ELISPOT assay. <i>Methods</i> , 2006, 38, 274-282.	1.9	100
60	The T cell response to persistent herpes virus infections in common variable immunodeficiency. <i>Clinical and Experimental Immunology</i> , 2006, 146, 234-242.	1.1	63
61	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. <i>Nature Medicine</i> , 2006, 12, 342-347.	15.2	1,865
62	Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: Concomitant assessment of perforin, IFN- γ and IL-4 secretion. <i>Journal of Immunological Methods</i> , 2006, 308, 216-230.	0.6	12
63	Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. <i>Journal of Immunological Methods</i> , 2006, 315, 121-132.	0.6	63
64	Rapid assessment of the antigenic integrity of tetrameric HLA complexes by human monoclonal HLA antibodies. <i>Journal of Immunological Methods</i> , 2006, 315, 153-161.	0.6	9
65	Flow cytometry controls, instrument setup, and the determination of positivity. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2006, 69A, 1037-1042.	1.1	296
66	Direct exosome stimulation of peripheral human T cells detected by ELISPOT. <i>European Journal of Immunology</i> , 2006, 36, 1772-1781.	1.6	237
67	Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. <i>International Journal of Cancer</i> , 2006, 118, 2514-2521.	2.3	12
68	Enzyme-Linked Immunosorbent Assay. , 2006, , 533-538.		6
69	Identification of Novel HLA-A*0201-Restricted Epitopes in Recent-Onset Type 1 Diabetic Subjects and Antibody-Positive Relatives. <i>Diabetes</i> , 2006, 55, 3061-3067.	0.3	83
70	Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8 + T-Cell Epitopes. <i>Journal of Virology</i> , 2006, 80, 4717-4728.	1.5	220
71	HIV-Specific Cytotoxic Cell Frequencies Measured Directly Ex Vivo by the Lysispot Assay Can Be Higher or Lower Than the Frequencies of IFN- γ -Secreting Cells: Anti-HIV Cytotoxicity Is Not Generally Impaired Relative to Other Chronic Virus Responses. <i>Journal of Immunology</i> , 2006, 176, 2662-2668.	0.4	17
72	Human Bone Marrow: A Reservoir for α Enhanced Effector Memory β -CD8+ T Cells with Potent Recall Function. <i>Journal of Immunology</i> , 2006, 177, 6730-6737.	0.4	45
73	Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 203-212.	0.9	101
74	Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 16233-16238.	3.3	118

#	ARTICLE	IF	CITATIONS
75	Enhanced Rates and Magnitude of Immune Responses Detected against an HIV Vaccine: Effect of Using an Optimized Process for Isolating PBMC. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 86-92.	0.5	71
76	A High Viral Burden Predicts the Loss of CD8 T-Cell Responses Specific for Subdominant Gag Epitopes during Chronic Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2007, 81, 13809-13815.	1.5	13
77	Substantial Improvements in Performance Indicators Achieved in a Peripheral Blood Mononuclear Cell Cryopreservation Quality Assurance Program Using Single Donor Samples. <i>Vaccine Journal</i> , 2007, 14, 52-59.	3.2	19
78	Establishing Acceptance Criteria for Cell-Mediated-Immunity Assays Using Frozen Peripheral Blood Mononuclear Cells Stored under Optimal and Suboptimal Conditions. <i>Vaccine Journal</i> , 2007, 14, 527-537.	3.2	85
79	Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. <i>Blood</i> , 2007, 109, 1138-1146.	0.6	51
80	Defining target antigens for CD25 + FOXP3 + IFN γ regulatory T cells in chronic hepatitis C virus infection. <i>Immunology and Cell Biology</i> , 2007, 85, 197-204.	1.0	50
81	Granzyme B production distinguishes recently activated CD8+ memory cells from resting memory cells. <i>Cellular Immunology</i> , 2007, 247, 36-48.	1.4	62
82	Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: Correlation of these functional T cell subsets with markers of disease progression. <i>Clinical Immunology</i> , 2007, 124, 57-68.	1.4	39
83	A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN γ HIV-specific immune responses. <i>Journal of Immunological Methods</i> , 2007, 320, 18-29.	0.6	42
84	Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. <i>Journal of Immunological Methods</i> , 2007, 322, 57-69.	0.6	206
85	The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 289-302.	2.0	138
86	Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 303-315.	2.0	193
87	Preliminary study on a potential panel for quality assurance of ELISPOT. <i>Virologica Sinica</i> , 2008, 23, 330-338.	1.2	0
88	A new approach for the large-scale generation of mature dendritic cells from adherent PBMC using roller bottle technology. <i>Journal of Immune Based Therapies and Vaccines</i> , 2008, 6, 1.	2.4	13
89	Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. <i>Immunome Research</i> , 2008, 4, 2.	0.1	293
90	Patients with Epstein Barr virus γ positive lymphomas have decreased CD4 ⁺ T γ cell responses to the viral nuclear antigen 1. <i>International Journal of Cancer</i> , 2008, 123, 2824-2831.	2.3	31
91	Polyfunctional HCV γ specific T γ cell responses are associated with effective control of HCV replication. <i>European Journal of Immunology</i> , 2008, 38, 2665-2677.	1.6	138
92	Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. <i>Vaccine</i> , 2008, 26, 1990-1998.	1.7	30

#	ARTICLE	IF	CITATIONS
93	Hepatitis C Virus-Specific T-Cell Gamma Interferon and Proliferative Responses Are More Common in Perihepatic Lymph Nodes than in Peripheral Blood or Liver. <i>Journal of Virology</i> , 2008, 82, 11742-11748.	1.5	7
94	Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8+ T cell immunity. <i>Journal of Leukocyte Biology</i> , 2008, 83, 1530-1540.	1.5	26
95	Hepatitis C Virus Immune Escape via Exploitation of a Hole in the T Cell Repertoire. <i>Journal of Immunology</i> , 2008, 181, 6435-6446.	0.4	61
96	Increased Frequency of EBV-Specific Effector Memory CD8+ T Cells Correlates with Higher Viral Load in Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2008, 181, 991-1000.	0.4	52
97	Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 2981-2986.	3.3	59
98	An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. <i>Journal of Experimental Medicine</i> , 2008, 205, 63-77.	4.2	273
99	Optimal Blood Mononuclear Cell Isolation Procedures for Gamma Interferon Enzyme-Linked Immunospot Testing of Healthy Swedish and Tanzanian Subjects. <i>Vaccine Journal</i> , 2008, 15, 585-589.	3.2	74
100	Broad Immunogenicity of a Multigene, Multiclade HIV-1 DNA Vaccine Boosted with Heterologous HIV-1 Recombinant Modified Vaccinia Virus Ankara. <i>Journal of Infectious Diseases</i> , 2008, 198, 1482-1490.	1.9	142
101	Differentiation of Human Embryonic Stem Cells into Immunostimulatory Dendritic Cells under Feeder-Free Culture Conditions. <i>Clinical Cancer Research</i> , 2008, 14, 6207-6217.	3.2	52
102	Peptide Impurities in Commercial Synthetic Peptides and Their Implications for Vaccine Trial Assessment. <i>Vaccine Journal</i> , 2008, 15, 267-276.	3.2	25
103	Magnitude, Breadth, and Functional Profile of T-Cell Responses during Human Immunodeficiency Virus Primary Infection with B and BF Viral Variants. <i>Journal of Virology</i> , 2008, 82, 2853-2866.	1.5	34
104	Dissociated Production of Perforin, Granzyme B, and IFN- γ by HIV-Specific CD8 ⁺ Cells in HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 62-71.	0.5	47
106	IFN- γ ELISPOT Assay Validation. , 0, , 147-172.		2
107	Endpoint Assays in HIV-1 Vaccine Trials: Functioning in a Good Laboratory Practices Environment. , 0, , 239-275.		1
108	PILAR is a novel modulator of human T-cell expansion. <i>Blood</i> , 2008, 112, 1259-1268.	0.6	37
109	Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients. <i>Journal of Immunotherapy</i> , 2008, 31, 101-112.	1.2	65
111	ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring even in hands of ELISPOT-inexperienced investigators. <i>Journal of Immunotoxicology</i> , 2009, 6, 227-234.	0.9	58
112	Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents. <i>Vaccine Journal</i> , 2009, 16, 147-155.	3.2	57

#	ARTICLE	IF	CITATIONS
113	Primary Human Immunodeficiency Virus Type 1-Specific CD8 ⁺ T-Cell Responses Induced by Myeloid Dendritic Cells. <i>Journal of Virology</i> , 2009, 83, 6288-6299.	1.5	30
114	Multiple T-Cell Responses to Human Immunodeficiency Virus Type 1 Are Enhanced by Dendritic Cells. <i>Vaccine Journal</i> , 2009, 16, 1504-1516.	3.2	12
115	Optimization of Human Immunodeficiency Virus Gag Expression by Newcastle Disease Virus Vectors for the Induction of Potent Immune Responses. <i>Journal of Virology</i> , 2009, 83, 584-597.	1.5	79
116	Humoral and Cellular Immune Responses after Influenza Vaccination in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2009, 9, 2346-2354.	2.6	110
117	Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 789-800.	2.0	16
118	The relationship between human effector and memory T cells measured by <i>ex vivo</i> and cultured ELISPOT following recent and distal priming. <i>Immunology</i> , 2009, 128, 83-91.	2.0	67
119	Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. <i>New England Journal of Medicine</i> , 2009, 361, 2209-2220.	13.9	2,748
120	Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. <i>Vaccine</i> , 2009, 27, 243-249.	1.7	55
121	Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4 ⁺ T-cell responses to internal proteins, hemagglutinins, and neuraminidases. <i>Human Immunology</i> , 2009, 70, 711-721.	1.2	57
122	AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. <i>Blood</i> , 2009, 114, 2077-2086.	0.6	248
123	Performance of serum-supplemented and serum-free media in IFN γ Elispot Assays for human T cells. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 609-618.	2.0	51
124	Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 799-803.	2.0	40
125	An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies. <i>Journal of Immunological Methods</i> , 2010, 360, 149-156.	0.6	15
127	Determination of rubella virus-specific cell-mediated immunity using IFN γ ELISpot. <i>Journal of Medical Virology</i> , 2010, 82, 335-340.	2.5	7
128	IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies. <i>British Journal of Cancer</i> , 2010, 102, 727-730.	2.9	26
129	Tracking Antigen-Specific T-Cells during Clinical Tolerance Induction in Humans. <i>PLoS ONE</i> , 2010, 5, e11028.	1.1	45
130	Dendritic Cells Reveal a Broad Range of MHC Class I Epitopes for HIV-1 in Persons with Suppressed Viral Load on Antiretroviral Therapy. <i>PLoS ONE</i> , 2010, 5, e12936.	1.1	14
131	Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate. <i>PLoS ONE</i> , 2010, 5, e13983.	1.1	72

#	ARTICLE	IF	CITATIONS
132	Detailed Characterization of T Cell Responses to Herpes Simplex Virus-2 in Immune Seronegative Persons. <i>Journal of Immunology</i> , 2010, 184, 3250-3259.	0.4	56
133	Quality Monitoring of HIV-1-Infected and Uninfected Peripheral Blood Mononuclear Cell Samples in a Resource-Limited Setting. <i>Vaccine Journal</i> , 2010, 17, 910-918.	3.2	20
134	Safety and Immunogenicity of Modified Vaccinia Ankara (ACAM3000): Effect of Dose and Route of Administration. <i>Journal of Infectious Diseases</i> , 2010, 201, 1361-1370.	1.9	69
135	A Phase 1/2 Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV-1-Uninfected East Africans (RV 172). <i>Journal of Infectious Diseases</i> , 2010, 201, 600-607.	1.9	100
136	Phase 1 Trial of Allogeneic Gene-Modified Tumor Cell Vaccine RCC-26/CD80/IL-2 in Patients with Metastatic Renal Cell Carcinoma. <i>Human Gene Therapy</i> , 2010, 21, 285-297.	1.4	19
137	Dual-Color ELISPOT Assay for the Simultaneous Detection of IL-2 and/or IFN- γ Secreting T Cells. <i>Cold Spring Harbor Protocols</i> , 2010, 2010, pdb.prot5369.	0.2	2
138	Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. <i>Annals of Neurology</i> , 2010, 67, 159-169.	2.8	181
139	Immunogenicity assay validation for an HIV vaccine trial: High IFN- γ /IL-2+ CD8+ T cells background in healthy Thais. <i>Vaccine</i> , 2011, 29, 6002-6007.	1.7	2
140	Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2. <i>Vaccine</i> , 2011, 29, 7058-7066.	1.7	12
141	Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. <i>Vaccine</i> , 2011, 29, 8417-8428.	1.7	97
142	A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells. <i>PLoS ONE</i> , 2011, 6, e24254.	1.1	8
143	Phase I Randomised Clinical Trial of an HIV-1CN54, Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally. <i>PLoS ONE</i> , 2011, 6, e25165.	1.1	52
144	Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2011, 92, 359-365.	0.5	19
145	Human keratinocytes release high levels of inducible heat shock protein 70 that enhances peptide uptake. <i>Experimental Dermatology</i> , 2011, 20, 637-641.	1.4	10
146	Quality assurance of intracellular cytokine staining assays: Analysis of multiple rounds of proficiency testing. <i>Journal of Immunological Methods</i> , 2011, 363, 143-157.	0.6	38
147	Stability and transport of cervical cytobrushes for isolation of mononuclear cells from the female genital tract. <i>Journal of Immunological Methods</i> , 2011, 367, 47-55.	0.6	17
148	Dana-Farber repository for machine learning in immunology. <i>Journal of Immunological Methods</i> , 2011, 374, 18-25.	0.6	32
149	Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11. <i>Cellular Immunology</i> , 2011, 270, 62-69.	1.4	48

#	ARTICLE	IF	CITATIONS
150	Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. <i>Journal of Translational Medicine</i> , 2011, 9, 26.	1.8	70
151	Differences in HIV-Specific T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals. <i>Journal of Virology</i> , 2011, 85, 3507-3516.	1.5	38
152	Interplay between Modified Vaccinia Virus Ankara and Dendritic Cells: Phenotypic and Functional Maturation of Bystander Dendritic Cells. <i>Journal of Virology</i> , 2011, 85, 5532-5545.	1.5	42
153	Human Leukocyte Antigen Variants B*44 and B*57 Are Consistently Favorable during Two Distinct Phases of Primary HIV-1 Infection in Sub-Saharan Africans with Several Viral Subtypes. <i>Journal of Virology</i> , 2011, 85, 8894-8902.	1.5	25
154	Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multi-peptide Melanoma Vaccine. <i>Journal of Clinical Oncology</i> , 2011, 29, 2924-2932.	0.8	102
155	Protective Role of Cytotoxic T Lymphocytes in Filovirus Hemorrhagic Fever. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-13.	3.0	18
156	How much of Virus-Specific CD8 T Cell Reactivity is Detected with a Peptide Pool when Compared to Individual Peptides?. <i>Viruses</i> , 2012, 4, 2636-2649.	1.5	15
157	A Live-Attenuated <i>Listeria</i> Vaccine (ANZ-100) and a Live-Attenuated <i>Listeria</i> Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction. <i>Clinical Cancer Research</i> , 2012, 18, 858-868.	3.2	304
158	Differential Patterns of Large Tumor Antigen-Specific Immune Responsiveness in Patients with BK Polyomavirus-Positive Prostate Cancer or Benign Prostatic Hyperplasia. <i>Journal of Virology</i> , 2012, 86, 8461-8471.	1.5	15
159	The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope. <i>Journal of Immunology</i> , 2012, 188, 5166-5176.	0.4	126
160	EBV-specific immune responses in patients with multiple sclerosis responding to IFN β therapy. <i>Multiple Sclerosis Journal</i> , 2012, 18, 605-609.	1.4	20
161	Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant. <i>Journal of Infectious Diseases</i> , 2012, 205, 1294-1304.	1.9	86
162	NYVAC immunization induces polyfunctional HIV-specific T cell responses in chronically infected, ART-treated HIV patients. <i>European Journal of Immunology</i> , 2012, 42, 3038-3048.	1.6	30
163	Peripheral blood responses to specific antigens and CD28 in sarcoidosis. <i>Respiratory Medicine</i> , 2012, 106, 701-709.	1.3	35
164	First analysis of human herpesvirus 6 T-cell responses: Specific boosting after HHV6 reactivation in stem cell transplantation recipients. <i>Clinical Immunology</i> , 2012, 144, 179-189.	1.4	12
165	Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection. <i>Virology Journal</i> , 2012, 9, 76.	1.4	10
166	T cell responses to hepatitis B splice-generated protein of hepatitis B virus and inflammatory cytokines/chemokines in chronic hepatitis B patients. ANRS study: HB EP 02 HBSP-FIBRO. <i>Journal of Viral Hepatitis</i> , 2012, 19, 872-880.	1.0	20
167	Cytomegalovirus (CMV)-Specific Perforin and Granzyme B ELISPOT Assays Detect Reactivation of CMV Infection in Inflammatory Bowel Disease. <i>Cells</i> , 2012, 1, 35-50.	1.8	13

#	ARTICLE	IF	CITATIONS
168	A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses. <i>Journal of Immunological Methods</i> , 2012, 375, 46-56.	0.6	11
169	Towards a xeno-free and fully chemically defined cryopreservation medium for maintaining viability, recovery, and antigen-specific functionality of PBMC during long-term storage. <i>Journal of Immunological Methods</i> , 2012, 382, 24-31.	0.6	25
170	Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the <i>Plasmodium falciparum</i> circumsporozoite protein (CSP). <i>Malaria Journal</i> , 2013, 12, 185.	0.8	30
171	Early Gag Immunodominance of the HIV-Specific T-Cell Response during Acute/Early Infection Is Associated with Higher CD8 ⁺ T-Cell Antiviral Activity and Correlates with Preservation of the CD4 ⁺ T-Cell Compartment. <i>Journal of Virology</i> , 2013, 87, 7445-7462.	1.5	53
172	Detection and preliminary characterization of CD8 ⁺ T lymphocytes specific for Wilms [™] tumor antigen in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2490-2499.	0.6	4
173	Targeted Coating With Antigenic Peptide Renders Tumor Cells Susceptible to CD8 ⁺ T Cell-mediated Killing. <i>Molecular Therapy</i> , 2013, 21, 542-553.	3.7	16
174	A Rationally Engineered Anti-HIV Peptide Fusion Inhibitor with Greatly Reduced Immunogenicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 679-688.	1.4	31
175	Profile of regulatory T cells and interferon γ secretion in the tumor-draining lymph node from mouse Hepa1 ⁶ cells. <i>Journal of Surgical Research</i> , 2013, 183, 900-906.	0.8	0
176	Silencing of the glucocorticoid-induced leucine zipper improves the immunogenicity of clinical-grade dendritic cells. <i>Cytotherapy</i> , 2013, 15, 740-749.	0.3	15
177	How frequently are predicted peptides actually recognized by CD8 cells? , 2013, 1, .		0
178	Suppression of Virus Specific Immune Responses by IL-10 in Acute Dengue Infection. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2409.	1.3	58
179	Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults. <i>Vaccine Journal</i> , 2013, 20, 397-408.	3.2	23
180	Quantitative and Qualitative Differences in the T Cell Response to HIV in Uninfected Ugandans Exposed or Unexposed to HIV-Infected Partners. <i>Journal of Virology</i> , 2013, 87, 9053-9063.	1.5	19
181	Detection of <i>E</i> <i>B</i> virus-specific memory CD ⁴ <i>T</i> cells using a peptide-based cultured enzyme-linked immunospot assay. <i>Immunology</i> , 2013, 139, 533-544.	2.0	28
182	Enumeration and Characterization of Human Memory T Cells by Enzyme-Linked Immunospot Assays. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	65
183	Mesoporous Silicon Microparticles Enhance MHC Class I Cross-Antigen Presentation by Human Dendritic Cells. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-9.	3.3	23
184	Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 527-537.	1.1	10
185	Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Vectors Prime for Strong Cellular Responses to Simian Immunodeficiency Virus Gag in Rhesus Macaques. <i>Vaccine Journal</i> , 2014, 21, 1385-1395.	3.2	13

#	ARTICLE	IF	CITATIONS
186	Quantification of circulating house dust mite-specific IL-4 and IL-13-secreting T cells correlates with rhinitis severity in asthmatic children and varies with the seasons. <i>Clinical and Experimental Allergy</i> , 2014, 44, 222-230.	1.4	17
187	Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. <i>Journal of Immunological Methods</i> , 2014, 409, 107-116.	0.6	34
188	Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients. <i>Transplant Immunology</i> , 2014, 30, 128-135.	0.6	4
189	Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study. <i>Vaccine</i> , 2014, 32, 4925-4931.	1.7	86
190	The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN- γ ELISpot) assay. <i>Journal of Immunological Methods</i> , 2014, 409, 31-43.	0.6	22
191	Differences in immune responses between CMV-seronegative and seropositive patients with myocardial ischemia and reperfusion. <i>Immunity, Inflammation and Disease</i> , 2015, 3, 56-70.	1.3	8
192	Human leukocyte antigens and genetic susceptibility to lymphoma. <i>Tissue Antigens</i> , 2015, 86, 98-113.	1.0	36
193	Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges. <i>Vaccines</i> , 2015, 3, 293-319.	2.1	26
194	Gliadin-Specific T-Cells Mobilized in the Peripheral Blood of Coeliac Patients by Short Oral Gluten Challenge: Clinical Applications. <i>Nutrients</i> , 2015, 7, 10020-10031.	1.7	18
195	Improvement of IFN γ ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis. <i>Cells</i> , 2015, 4, 1-18.	1.8	22
196	Human Papillomavirus 16-Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions. <i>Journal of Infectious Diseases</i> , 2015, 211, 405-415.	1.9	29
197	Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications. <i>Journal of Clinical Virology</i> , 2015, 70, 109-119.	1.6	20
198	Guidelines for the automated evaluation of Elispot assays. <i>Nature Protocols</i> , 2015, 10, 1098-1115.	5.5	74
199	Functionality of Dengue Virus Specific Memory T Cell Responses in Individuals Who Were Hospitalized or Who Had Mild or Subclinical Dengue Infection. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003673.	1.3	41
200	Long-lasting stem cell-like memory CD8 ⁺ T cells with a naïve-like profile upon yellow fever vaccination. <i>Science Translational Medicine</i> , 2015, 7, 282ra48.	5.8	174
201	Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 686-691.	0.9	26
202	Persistence of mucosal T-cell responses to herpes simplex virus type 2 in the female genital tract. <i>Mucosal Immunology</i> , 2015, 8, 115-126.	2.7	28
203	Methods for Detection of Antigen-Specific T Cells by Enzyme-Linked Immunospot Assay (ELISPOT). , 0, , 290-295.		0

#	ARTICLE	IF	CITATIONS
204	Norovirus-Specific Memory T Cell Responses in Adult Human Donors. <i>Frontiers in Microbiology</i> , 2016, 7, 1570.	1.5	29
205	The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function. <i>Scientific Reports</i> , 2016, 6, 30749.	1.6	61
206	An antigen-specific, four-color, B-cell FluoroSpot assay utilizing tagged antigens for detection. <i>Journal of Immunological Methods</i> , 2016, 433, 23-30.	0.6	21
207	Variability of the IFN- γ ELISpot assay in the context of proficiency testing and bridging studies. <i>Journal of Immunological Methods</i> , 2016, 433, 69-76.	0.6	6
208	Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1189-1199.	2.0	38
209	Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1201-1212.	2.0	36
210	Stroke induces specific alteration of T memory compartment controlling auto-reactive CNS antigen-specific T cell responses. <i>Journal of the Neurological Sciences</i> , 2016, 368, 77-83.	0.3	16
211	How frequently are predicted peptides actually recognized by CD8 cells?. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 847-855.	2.0	32
212	Macrophage Inflammatory Protein-1 Beta and Interferon Gamma Responses in Ugandans with HIV-1 Acute/Early Infections. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 237-246.	0.5	7
213	Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 1035-1044.	2.9	63
214	Regulatory T Cell Effect on CD8 ⁺ T Cell Responses to Human Herpesvirus 8 Infection and Development of Kaposi's Sarcoma. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 668-674.	0.5	13
215	Development of an epitope panel for consistent identification of antigen-specific T cells in humans. <i>Immunology</i> , 2017, 152, 298-307.	2.0	1
216	Impact of HLA-DRB1 allele polymorphisms on control of HIV infection in a Peruvian MSM cohort. <i>Hla</i> , 2017, 90, 234-237.	0.4	6
217	Evaluation of Different Parameters of Humoral and Cellular Immune Responses in HIV Serodiscordant Heterosexual Couples: Humoral Response Potentially Implicated in Modulating Transmission Rates. <i>EBioMedicine</i> , 2017, 26, 25-37.	2.7	15
218	Differences in peripheral myelin antigen-specific T cell responses and T memory subsets in atypical versus typical CIDP. <i>BMC Neurology</i> , 2017, 17, 81.	0.8	18
219	Delayed Activation Kinetics of Th2- and Th17 Cells Compared to Th1 Cells. <i>Cells</i> , 2017, 6, 29.	1.8	19
220	A Positive Control for Detection of Functional CD4 T Cells in PBMC: The CPI Pool. <i>Cells</i> , 2017, 6, 47.	1.8	24
221	Neurofascin (NF)155- and NF186-Specific T Cell Response in a Patient Developing a Central Pontocerebellar Demyelination after 10 Years of CIDP. <i>Frontiers in Neurology</i> , 2017, 8, 724.	1.1	9

#	ARTICLE	IF	CITATIONS
222	Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma. <i>Stem Cell Investigation</i> , 2017, 4, 77-77.	1.3	22
223	Whole Recombinant <i>Saccharomyces cerevisiae</i> Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial. <i>Journal of Immunotherapy</i> , 2018, 41, 141-150.	1.2	21
224	Phenotype, Polyfunctionality, and Antiviral Activity of in vitro Stimulated CD8+ T-Cells From HIV+ Subjects Who Initiated cART at Different Time-Points After Acute Infection. <i>Frontiers in Immunology</i> , 2018, 9, 2443.	2.2	12
225	KIR3DL1-Negative CD8 T Cells and KIR3DL1-Negative Natural Killer Cells Contribute to the Advantageous Control of Early Human Immunodeficiency Virus Type 1 Infection in HLA-B Bw4 Homozygous Individuals. <i>Frontiers in Immunology</i> , 2018, 9, 1855.	2.2	8
226	Cultured ELISpot Assay to Investigate Dengue Virus Specific T-Cell Responses. <i>Methods in Molecular Biology</i> , 2018, 1808, 165-171.	0.4	17
227	Neurofascin and Compact Myelin Antigen-Specific T Cell Response Pattern in Chronic Inflammatory Demyelinating Polyneuropathy Subtypes. <i>Frontiers in Neurology</i> , 2018, 9, 171.	1.1	10
228	High-Throughput GLP-Capable Target Cell Visualization Assay for Measuring Cell-Mediated Cytotoxicity. <i>Cells</i> , 2018, 7, 35.	1.8	9
229	Direct Detection of T- and B-Memory Lymphocytes by ImmunoSpot® Assays Reveals HCMV Exposure that Serum Antibodies Fail to Identify. <i>Cells</i> , 2018, 7, 45.	1.8	11
230	A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. <i>Blood</i> , 2018, 132, 1911-1921.	0.6	44
231	Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency. <i>PLoS ONE</i> , 2019, 14, e0223861.	1.1	3
232	Extracellular pH modulating injectable gel for enhancing immune checkpoint inhibitor therapy. <i>Journal of Controlled Release</i> , 2019, 315, 65-75.	4.8	26
233	Restored and Enhanced Memory T Cell Immunity in Rheumatoid Arthritis After TNF± Blocker Treatment. <i>Frontiers in Immunology</i> , 2019, 10, 887.	2.2	5
234	Natural T cell autoreactivity to melanoma antigens: clonally expanded melanoma-antigen specific CD8+ memory T cells can be detected in healthy humans. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 709-720.	6.0	20
235	Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 141-149.	0.5	223
236	Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. <i>Immunity</i> , 2020, 53, 1095-1107.e3.	6.6	273
237	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
238	Functional comparison of PBMCs isolated by Cell Preparation Tubes (CPT) vs. Lymphoprep Tubes. <i>BMC Immunology</i> , 2020, 21, 15.	0.9	27
239	Targeted tumor coating with antigenic, CTL-recognizable peptides via Annexin A5 chimeric constructs following chemotherapy redirects adaptive CD8+ T cell immunity for tumor clearance. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1578-1580.	4.8	3

#	ARTICLE	IF	CITATIONS
240	Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization. <i>Cancers</i> , 2021, 13, 223.	1.7	7
241	CERI, CEFX, and CPI: Largely Improved Positive Controls for Testing Antigen-Specific T Cell Function in PBMC Compared to CEF. <i>Cells</i> , 2021, 10, 248.	1.8	9
242	Antigen identification for HLA class II ⁺ and HLA class II ⁻ restricted T cell receptors using cytokine-capturing antigen-presenting cells. <i>Science Immunology</i> , 2021, 6, .	5.6	22
243	Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials. <i>African Journal of Laboratory Medicine</i> , 2021, 10, 1056.	0.2	5
244	Macrophage Plasticity and Function in the Lung Tumour Microenvironment Revealed in 3D Heterotypic Spheroid and Explant Models. <i>Biomedicines</i> , 2021, 9, 302.	1.4	9
245	CD4+ T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike Glycoprotein. <i>Frontiers in Immunology</i> , 2021, 12, 629102.	2.2	8
247	Alternative Evaluation of an ELISPOT Assay Using Cytokine Activity as a Novel Parameter. <i>Anticancer Research</i> , 2021, 41, 3825-3831.	0.5	2
248	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund [™] s adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20
249	Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund [™] s adjuvant, cyclophosphamide, and polyI:CLC (Mel63). , 2021, 9, e000934.		14
250	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. <i>Oncolmmunology</i> , 2021, 10, 1898105.	2.1	11
251	The Quantification of Antigen-Specific T Cells by IFN- γ ELISpot. <i>Methods in Molecular Biology</i> , 2021, 2183, 525-536.	0.4	10
252	Quantifying HIV-1-Specific CD8 + T-Cell Responses Using ELISPOT and Cytokine Flow Cytometry. <i>Methods in Molecular Biology</i> , 2009, 485, 359-374.	0.4	5
253	The Impact of Harmonization on ELISPOT Assay Performance. <i>Methods in Molecular Biology</i> , 2012, 792, 25-36.	0.4	38
256	Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. <i>Journal of Clinical Investigation</i> , 2017, 127, 3126-3135.	3.9	165
257	Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa. <i>PLoS ONE</i> , 2010, 5, e12873.	1.1	86
258	Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories. <i>PLoS ONE</i> , 2010, 5, e14330.	1.1	47
259	Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors. <i>PLoS ONE</i> , 2011, 6, e18164.	1.1	46
260	Evaluation of Approaches to Identify the Targets of Cellular Immunity on a Proteome-Wide Scale. <i>PLoS ONE</i> , 2011, 6, e27666.	1.1	14

#	ARTICLE	IF	CITATIONS
261	Induction of Multi-Functional T Cells in a Phase I Clinical Trial of Dendritic Cell Immunotherapy in Hepatitis C Virus Infected Individuals. PLoS ONE, 2012, 7, e39368.	1.1	8
262	HIV-1 Envelope Resistance to Proteasomal Cleavage: Implications for Vaccine Induced Immune Responses. PLoS ONE, 2012, 7, e42579.	1.1	13
263	Early Skewed Distribution of Total and HIV-Specific CD8+ T-Cell Memory Phenotypes during Primary HIV Infection Is Related to Reduced Antiviral Activity and Faster Disease Progression. PLoS ONE, 2014, 9, e104235.	1.1	28
264	A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS. PLoS ONE, 2014, 9, e115161.	1.1	48
265	Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial. PLoS ONE, 2015, 10, e0119629.	1.1	43
266	Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo. PLoS Pathogens, 2017, 13, e1006232.	2.1	14
267	Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma. Oncotarget, 2015, 6, 1115-1127.	0.8	40
268	Protective Immunodominant Zaire Ebolavirus Glycoprotein Epitope in Mice. Journal of Bioterrorism & Biodefense, 2011, 01, .	0.1	2
269	TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway. ELife, 2017, 6, .	2.8	66
271	Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome. , 2006, , 459-470.		0
272	Planning the Experiment. Techniques in Life Science and Biomedicine for the Non-expert, 2016, , 43-48.	0.1	2
273	Sample Preparation. Techniques in Life Science and Biomedicine for the Non-expert, 2016, , 25-41.	0.1	0
276	Detection and Enumeration of Cytokine-Secreting Cells by. Methods in Molecular Biology, 2022, 2386, 81-99.	0.4	2
277	Detection of Cytokine-Secreting Cells by Enzyme-Linked Immunospot (ELISpot). Methods in Molecular Biology, 2022, 2386, 61-79.	0.4	3
278	Control of Tumors by Antigen-Specific CD8+ T Cells through PDL1-Targeted Delivery of Antigenic Peptide. Journal of Immunology Research, 2022, 2022, 1-8.	0.9	0
279	Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nature Communications, 2022, 13, 153.	5.8	45
280	Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays. MAbs, 2022, 14, 1993522.	2.6	25
291	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. Nature Communications, 2022, 13, .	5.8	28

#	ARTICLE	IF	CITATIONS
292	Diverse CD8+ T-Cell Responses to Renal Cell Carcinoma Antigens in Patients Treated with an Autologous Granulocyte-Macrophage Colony-Stimulating Factor Gene-Transduced Renal Tumor Cell Vaccine. <i>Cancer Research</i> , 2005, 65, 1079-1088.	0.4	32
293	Enhanced <i>In Vitro</i> and <i>In Vivo</i> Potency of a T Cell Epitope in the Ebola Virus Glycoprotein Following Amino Acid Replacement at HLA-A*02:01 Binding Positions. <i>Journal of Virology</i> , 2022, 96, .	1.5	1
294	Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64). , 2022, 10, e005424.		7
295	Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy. <i>AAPS Journal</i> , 2023, 25, .	2.2	6
299	Important Considerations for ELISpot Validation. <i>Methods in Molecular Biology</i> , 2024, , 1-13.	0.4	0